

Comparative Evaluation of SARS-CoV-2 IgG Assays in India

*DBT India Consortium for Covid-19 Research**

*The members of the consortium and the writing committee are listed at the end of the article.

Corresponding author:

Professor Shinjini Bhatnagar,

Translational Health Science and Technology Institute,

(Autonomous institute of the Dept of Biotechnology, Govt of India)

NCR Biotech Science Cluster, 3rd Milestone, Faridabad–Gurugram Expressway,

PO box #04, Faridabad - 121001 (Haryana), India

Shinjini.bhatnagar@thsti.res.in

Word count – abstract: 157

Word count – text: 2405

Abstract:

IgG immunoassays have been developed and used widely for clinical samples and serosurveys for SARS-CoV-2. We compared the performance of three immunoassays, an in-house RBD assay, and two commercial assays, the Diasorin LIAISON SARS-CoV-2 IgG CLIA which detects antibodies against S1/S2 domains of the Spike protein and the Zydus Kavach assay based on inactivated virus using a well-characterized sera-panel. 379 sera/plasma samples from RT-PCR positive individuals >20 days of illness in symptomatic or RT-PCR positivity in asymptomatic individuals and 184 pre-pandemic samples were used. The sensitivity of the assays were 84.7, 82.6 and 75.7 respectively for RBD, LIAISON and Kavach. Kavach and the in-house RBD ELISA showed a specificity of 99.5% and 100%, respectively. The RBD and LIAISON (S1/S2) assays showed high agreement (94.7%;95%CI:92.0,96.6) and were able to correctly identify more positives than Kavach. All three assays are suitable for serosurveillance studies, but in low prevalence sites, estimation of exposure may require adjustment based on our findings.

Keywords: SARS-CoV-2, Covid-19, seroconversion, IgG, Immunoassay, sensitivity, specificity, LIAISON SARS-CoV-2 S1/S1 IgG, Zydus Kavach, RBD IgG ELISA

Abbreviations: RBD – Receptor Binding Domain, CLIA – Chemi-Luminescence Immuno Assay, ELISA: Enzyme Linked ImmunoSorbent Assay, MHRA – The UK Medicines and Healthcare products Regulatory Agency

1 Introduction

2 Nucleic acid-based diagnostic tests like RT-PCR have shown considerable sensitivity
3 and specificity for detection of active SARS-CoV-2 infections and are being used as the
4 primary diagnostic tool. Serological tests, on the other hand, are important tools for
5 estimation of seroprevalence of the disease at a community level. At an individual level,
6 serological evidence may be a correlate of exposure or vaccine response.

7 Performance characteristics of serological tests determine their utility and interpretation
8 of results. For SARS-CoV2, many tests have been developed but there are limited
9 direct comparisons. Approximately 390 tests for IgG, IgM, IgA and total antibody have
10 been developed across a range of platforms including chemiluminescence, magnetic
11 bead-based assays, microwell ELISA, lateral flow, etc. using different portions of the
12 spike and nucleocapsid proteins as well as whole inactivated virus [1]. Although the
13 nucleocapsid is more abundant and immunogenic, most assays in use or in
14 development have utilized different regions of the spike protein or whole virus as the
15 capture reagent in immunoassays. This is mainly because anti- spike antibodies are
16 believed to be less cross-reactive based on viral spike homology and are expected to
17 correlate better with neutralizing capacity of convalescent sera. Most of these assays
18 have been developed rapidly, many under emergency use authorization, and hence
19 were evaluated by the developers in a limited set of samples. The performance of these
20 assays in larger sample sets in various real-world setting is necessary to interpret the
21 results of the seroepidemiological studies conducted using these assays.

22 In this study, we evaluate three serological tests, one in-house ELISA, a commercial
23 ELISA, and a commercial chemiluminescence immunoassay and report their sensitivity
24 based on 379 RT-PCR positive convalescent sera and plasma samples collected from a
25 prospective cohort of COVID-19 positive participants and specificity based on 184 pre-
26 pandemic participants. We also perform head-to-head analyses of their ability to
27 correctly identify IgG positive samples.

28 **Materials and Methods**

29 Participants for serological assay comparison

30 The participants for this study were derived from a longitudinal cohort of COVID-19
31 positive participants known as the Department of Biotechnology India COVID-19
32 Consortium cohort, with ongoing recruitment from March 2020 at eight clinical sites in
33 the Delhi- National Capital Region, India. The participants in this cohort are derived from
34 two types of enrollment: i) Suspected COVID-19 patients enrolled at the time of RT-
35 PCR testing at the screening center and ii) RT-PCR confirmed COVID-19 positive
36 patients admitted at one of the clinical sites. The testing by RT-PCR was done at an
37 approved laboratory as per the National Testing Strategy of India [2]. The RT-PCR
38 confirmed COVID-19 patients were followed up at 10-28 days and 6-8 weeks of onset of
39 illness. During the enrollment and follow-up detailed clinical information on the exposure
40 history, clinical features and comorbidities were documented. Venous blood samples
41 are collected, transported, processed and stored per protocol [3]. All enrollments were
42 made after an informed consent process and the study protocol was approved by the
43 Institute Ethics Committees of the participating research institutes and hospitals.

44 The COVID-19 positive reference standard sera panel (n=379) was formed using the
45 sera/plasma samples collected ≥ 20 days of illness or following RT-PCR positivity. This
46 criterion is in alignment with the UK Medicines and Healthcare products Regulatory
47 Agency (MHRA) to improve comparability [4,5]. The duration of illness for asymptomatic
48 participants was calculated from their date of diagnosis. For symptomatic participants, it
49 was calculated from the date of testing or date of onset of symptoms whichever was the
50 earlier. The COVID-19 negative standard panel was built from sera samples collected in
51 the pre-pandemic period (184 from pregnant women enrolled in a pregnancy cohort) to
52 ensure a clean set of negative samples[4–6].

53 Index test methods and alternate reference tests

54 Index test: THSTI In-house RBD IgG ELISA

55 SARS-CoV-2 RBD protein was diluted to $2\mu\text{g/ml}$ in PBS pH 7.4 and $50\mu\text{l/well}$ was
56 coated on maxisorp polystyrene plate (Thermo Scientific). Plates were incubated at 4°C
57 for overnight. Next day, the wells were washed 3 times with PBST (PBS with 0.1%
58 Tween 20) using 96-well plate-washer (Tecan AG). Two hundred microliter of blocking
59 solution (PBST with 3% skim milk) was added to all the wells. The Plates were
60 incubated at 20°C for 2 hours. After 2 hours of incubation, plates were removed from
61 the incubator and the blocking solution was thrown off. Hundred microliter of diluted test
62 serum or control samples (1:50 dilution in PBST with 1% skim milk) were added to the
63 appropriate wells and the plates were incubated at 20°C . After 2 hours of incubation,
64 plates were removed from the incubator and washed 3 times with PBST. Horse Radish
65 Peroxidase labeled goat anti-Human IgG Fc γ -sp. Tracer antibody (Jackson Immuno

66 Research, Pennsylvania, USA) was diluted 1:5000 in PBST with 1% skim milk and 50 μ l
67 of diluted tracer was added in each well of the plates. Plates were incubated in a 20°C
68 incubator for 1 hour. After the completion of the incubation period, plates were washed
69 3 times with PBST and in each well 100 μ l of TMB substrate (BD Biosciences) was
70 added and plates were incubated at room temperature for 10 min in dark. Fifty microliter
71 of stop solution (1M H₂SO₄) was added in each well and the absorbance was measured
72 using a microplate reader (Biorad, California, USA) at 450 nm with 650 nm as reference
73 wavelength. In each assay, 8 known negative samples with variable background were
74 used as control to calculate the cut-off value. The cut-off value was calculated using the
75 formula: Cut-off = Average OD value of negative control samples + 3* SD of OD value
76 of negative control samples

77 Covid Kavach IgG ELISA

78 Covid Kavach IgG ELISA was developed by the Indian Council of Medical Research's
79 National Institute of Virology, and manufactured by Zydus [7]. The test was performed
80 as per manufacturer's instructions. The kit suggests interpretation of the results by a
81 two-pronged method, based on OD value and P/N (Positive/Negative Ratio). When both
82 read-outs are in agreement, then the sample is considered positive or negative. The
83 manufacturer's instruction does not mention interpretation for samples with a read-out
84 not in agreement for the two criteria. We considered such results negative.

85 DiaSorin CLIA

86 The LIAISON SARS-CoV-2 S1/S2 IgG chemiluminescence assay manufactured by
87 DiaSorin was also used for comparison. This test uses S1/S2 antigens to capture

88 specific IgG antibodies. The test was performed as per manufacturer's instructions, with
89 calibration and positive and negative controls run before each batch of antibody testing
90 as per manufacturer's protocol [8]. The tests were considered positive when the IgG
91 concentration was ≥ 15 AU/mL, negative when the concentration was < 12 AU/mL and
92 equivocal when the concentration was > 12 and < 15 AU/mL. Equivocal samples were
93 considered negative for sensitivity analysis.

94 Statistical analysis

95 In the absence of a gold standard for SARS-CoV-2 IgG immunoassays, an alternate
96 reference standard was used for this study, which is SARS-COV-2 RT-PCR positivity
97 with > 20 days duration of illness (symptomatic) or > 20 days beyond RT-PCR positivity
98 (asymptomatic). While comparing the three assays, we report sensitivity and specificity
99 of each test with the positive and negative reference standards as defined. In addition,
100 we performed a head-to-head analysis for agreement between these methods. We
101 estimated the global agreement calculated as the sum of the number of positives by
102 both methods and number negative by both divided by the total number of samples. We
103 estimated the bias index defined as the difference in the proportion of positivity for any
104 bias between the methods to check whether one method was superior to the other in
105 correctly identifying positive samples. As the prevalence of positives and negatives may
106 play a role in the interpretation of the kappa statistic, we report the prevalence index
107 defined as difference between probability of positives and probability of negatives. We
108 finally report the kappa statistic adjusted for prevalence and bias known as prevalence
109 and bias-adjusted kappa [9]. We then compared the sensitivity of the three candidate
110 tests across different periods of illness. All analyses were done using the STATA-SE-15

111 software (Texas, USA) and the Kappa coefficient and related indices were estimated
112 using Cohenkap package for STATA [10].

113 **Results**

114 Samples defined by an Alternate Reference Standard used for comparative evaluation

115 The reference true positive sample panel consisted of 379 samples from 368
116 participants; 11 of whom provided two samples at different time-points. The distribution
117 of the duration of illness was bimodal owing to the design of the cohort from which the
118 samples were derived. The means of the sampling window distributions are 23.5 and
119 49.3 days respectively (Supplementary figure 2). Most samples (83.7%) were obtained
120 from symptomatic individuals. Nearly half of the samples were sera, rest were plasma.
121 The reference negative panel consisted of 184 pre-pandemic samples collected before
122 September 2019.

123

124 Comparison of the sensitivity and specificity of candidate assays

125 Among the three candidate tests, RBD IgG ELISA demonstrated the highest sensitivity
126 (84.7; 95%CI: 80.6 - 88.1) and Zydus Kavach the least (75.7; 95%CI: 71.0 - 79.9).
127 Zydus Kavach is interpreted as positive when both test parameters were positive based
128 on cut-Off and P/N ratio. Six samples were indeterminate in Zydus Kavach test; and 25
129 samples were positive only by one condition (Cut-off, P/N ratio) by Zydus Kavach.
130 Seven samples were reported as indeterminate by DiaSorin CLIA. When Zydus Kavach
131 was interpreted as positive with one of the two criteria, 25 additional samples were
132 identified as positive, improving the sensitivity to 81.8%. The sensitivities of the tests did
133 not change with the increase in the duration of illness beyond 20 days (Supplementary

134 table 5). The specificities of Zydus Kavach and RBD ELISA were 99.5 and 100%
 135 respectively (Table-1, Figure-1). The specificity of DiaSorin could not be evaluated due
 136 to limited availability of pre-pandemic negative sera.

137


Tests	Sensitivity (95%CI)	Specificity
Zydus-Kavach	75.7 (71.0 - 79.9)	99.5%
DiaSorin CLIA	82.6 (78.3 - 86.2)	---
RBD ELISA	84.7 (80.6 - 88.1)	100%

138

139 **Table 1: Sensitivity (%) and specificity (%) of Zydus-Kavach, DiaSorin CLIA &**
 140 **THSTI-RBD ELISA**

141 Total true positive samples evaluated: 379; true negative samples: 184

142 The specificity of DiaSorin could not be evaluated due to limited availability of pre-
 143 pandemic negative sera.



144

145 **Figure 1. Plot of sensitivity (95% confidence intervals) for the candidate assays**

146 The dots represent the sensitivity (%) and the bars, 95% CI.

147

148 Comparison of Zydus-Kavach, DiaSorin CLIA & RBD ELISA

149 When evaluated for agreement between the tests, DiaSorin CLIA and RBD ELISA had
 150 highest concordance with a global agreement of 94.7% (95%CI: 92.0, 96.6). There was
 151 minimal bias between the two tests; with just 6 samples positive with DiaSorin labelled
 152 negative by RBD ELISA. Among the other 14 discordant samples that were positive by
 153 RBD ELISA, five were equivocal by DiaSorin and the rest were negative. The
 154 agreement estimated by prevalence and bias-adjusted kappa statistic (0.89) was near
 155 perfect between the two tests (Table-2 & Supplementary table-4).

156 On the other hand, head-to-head comparison of DiaSorin CLIA and RBD ELISA against
 157 Zydus Kavach demonstrated that the degrees of agreement were modest. The global
 158 agreement between the pairs of DiaSorin CLIA and Zydus Kavach, and RBD ELISA and
 159 Zydus Kavach were 88.7% (95%CI: 85.1, 91.5) and 87.3% (95%CI: 83.6, 90.3)
 160 respectively (Table-2). DiaSorin CLIA and RBD ELISA were superior to Zydus Kavach
 161 ELISA and were able to correctly identify 7% and 9% more IgG positive sera than the
 162 latter (Supplementary tables 2 & 3).

<i>Kit</i>	<i>Zydus-Kavach</i>	<i>DiaSorin CLIA</i>	<i>RBD ELISA</i>
<i>Zydus-Kavach</i>		88.7% (95%CI: 85.1, 91.5)	87.3% (95%CI: 83.6, 90.3)
<i>DiaSorin CLIA</i>	0.77		94.7% (95%CI: 92.0, 96.6)
<i>RBD ELISA</i>	0.75	0.89	

163

164 **Table 2: Head-to-head comparison of Zydus-Kavach, DiaSorin CLIA & RBD ELISA**

165 Numbers in the cells below the diagonal in the table denote Prevalence and Bias
 166 adjusted Kappa statistic. Numbers in the cells above the diagonal in the table denote
 167 agreement and 95%CI calculated as (positive by both methods + negative by both)/
 168 total samples

169 Discussion

170 Comparison of three assays on a well-characterized sample set showed that the
171 DiaSorin CLIA and the in-house RBD ELISA performed slightly better than the Zydus
172 Kavach ELISA with higher sensitivity and ability to identify more IgG positive samples.
173 These results are important as they help interpretation of the serosurveillance studies
174 that are being conducted in India using these tests.

175 The sensitivities reported in our study are less than reported by the companies or
176 elsewhere [5,7]. An independent evaluation of DiaSorin CLIA, the sensitivity was
177 reported to be 95.0% (95%CI: 92.8, 96.7), which is at least 13 percentage points higher
178 than this report [3]. While unlikely, this difference could be attributed to false positives
179 in our RT-PCR assay since we used RT-PCR positive convalescent samples as
180 reference standards. Similarly, the article reporting internal validation of Zydus Kavach
181 ELISA reported a sensitivity of 92.37% based on samples that were positive in a micro-
182 neutralization assay as against 75.7% that we see in our study using sera collected >20
183 days post-RT-PCR positivity [7]. While we harmonised our definition of positive
184 reference standard with that of the UK MHRA, about 14% of our participants were
185 asymptomatic, and may have had a lower antibody response as reported in a
186 longitudinal study, albeit with small numbers, which showed that 2/24 of their
187 participants did not seroconvert when followed up 20-28 days into their illness [11].

188 To overcome the limitation of an imperfect positive reference standard and to improve
189 inferences, the relative performance of these tests was evaluated by head-to-head
190 comparison. RBD ELISA and DiaSorin CLIA were able to identify more positive IgG

191 sera/plasma than Zydus Kavach. However, RBD ELISA is an in-house ELISA
192 developed using similar sample collections. While the sample panel used for evaluation
193 was independent of that used in the development of the RBD ELISA, its true test would
194 be when it is evaluated externally.

195 Highly sensitive serological assays can assess immune response to SARS-CoV-2 and
196 are needed to determine the extent of spread of the virus, which in turn is critical for
197 assessing case fatality rates and herd immunity. Serological assays also help in
198 assessing development of herd immunity to devise community management strategies
199 that are of crucial importance at this time, and will continue to be relevant in the coming
200 years. Other uses of serological assays can be to assess exposure in high-risk
201 populations such as healthcare workers and assess vaccination strategy at state or
202 national level. Cross-reactivity with SARS-CoV and seasonal coronaviruses in different
203 population and timing of IgM and IgG responses need to continue to be considered. Till
204 date, studies on comparative performance serological assays for SARS-CoV-2 show a
205 range of sensitivity of 84-98% and specificity of 96-99% [12–29]. Two of the three IgG
206 assays in this study used the Spike protein (Receptor binding domain or RBD in THSTI-
207 In-house ELISA and S1/S2 in DiaSorin CLIA), while the specific antigenic epitope(s) of
208 the inactivated virus in the Kavach assay are not defined. Since RBD in the spike
209 protein is the major site of ACE-2 binding, assays with this target may have more
210 concordance with neutralizing antibodies. The spike protein has more CD4 and CD8 T
211 cell immunodominant epitopes as experimentally shown in SARS-CoV, and since these
212 epitopes are mostly conserved even in SARS-CoV-2 isolates, serological assays

213 targeting RBD or full length S1/S2 are putatively more appropriate for assessing long-
214 term immune status [30].

215 **Conclusion:**

216 Overall, this is the first comparative study of SARS-CoV-2 IgG assays in India evaluated
217 independently against a strategically designated alternate reference standard. One
218 limitation of this study is that we were unable to evaluate the specificity of the Diasorin
219 assay due to paucity of negative samples. Nonetheless, the well characterized panels
220 provide useful information for decision-making for choice of serological assays.

221 References

- 222 [1] SARS-CoV-2 diagnostic pipeline, FIND. <https://www.finddx.org/covid-19/pipeline/>
223 (accessed August 8, 2020).
- 224 [2] Strategy for COVID-19 testing in
225 India. [https://www.icmr.gov.in/pdf/covid/strategy/Testing_Strategy_v5_18052020.p](https://www.icmr.gov.in/pdf/covid/strategy/Testing_Strategy_v5_18052020.pdf)
226 [df](https://www.icmr.gov.in/pdf/covid/strategy/Testing_Strategy_v5_18052020.pdf) (accessed August 7, 2020)
- 227 [3] SOP_Specimen_Collection_2019-
228 nCoV.pdf. https://niv.co.in/SOP_Specimen_Collection_2019-nCoV.pdf (accessed
229 August 7, 2020).
- 230 [4] Target Product Profile: enzyme Immunoassay (EIA) Antibody tests to help
231 determine if people have antibodies to SARS-CoV-2,
232 GOV.UK. [https://www.gov.uk/government/publications/how-tests-and-testing-kits-](https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/target-product-profile-enzyme-immunoassay-eia-antibody-tests-to-help-determine-if-people-have-antibodies-to-sars-cov-2)
233 [for-coronavirus-covid-19-work/target-product-profile-enzyme-immunoassay-eia-](https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/target-product-profile-enzyme-immunoassay-eia-antibody-tests-to-help-determine-if-people-have-antibodies-to-sars-cov-2)
234 [antibody-tests-to-help-determine-if-people-have-antibodies-to-sars-cov-2](https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/target-product-profile-enzyme-immunoassay-eia-antibody-tests-to-help-determine-if-people-have-antibodies-to-sars-cov-2)
235 (accessed August 7, 2020).
- 236 [5] Public Health England Porton Down, Evaluation of sensitivity and specificity of four
237 commercially available SARS-CoV-2 antibody immunoassays, Public Health
238 England, Porton Down Nuffield Department of Medicine, University of Oxford
239 Oxford University Hospitals NHS Foundation
240 Trust, [https://assets.publishing.service.gov.uk/government/uploads/system/uploads](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/898437/Evaluation_of_sensitivity_and_specificity_of_4_commercially_available_SARS-CoV-2_antibody_immunoassays.pdf)
241 [/attachment_data/file/898437/Evaluation_of_sensitivity_and_specificity_of_4_com](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/898437/Evaluation_of_sensitivity_and_specificity_of_4_commercially_available_SARS-CoV-2_antibody_immunoassays.pdf)
242 [mercially_available_SARS-CoV-2_antibody_immunoassays.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/898437/Evaluation_of_sensitivity_and_specificity_of_4_commercially_available_SARS-CoV-2_antibody_immunoassays.pdf) (accessed August
243 7, 2020).

- 244 [6] S. Bhatnagar, P.P. Majumder, D.M. Salunke, Interdisciplinary Group for Advanced
245 Research on Birth Outcomes—DBT India Initiative (GARBH-Ini), A Pregnancy
246 Cohort to Study Multidimensional Correlates of Preterm Birth in India: Study
247 Design, Implementation, and Baseline Characteristics of the Participants, American
248 Journal of Epidemiology. 188 (2019) 621–631. <https://doi.org/10.1093/aje/kwy284> .
- 249 [7] G. Sapkal, A. Shete-Aich, R. Jain, P.D. Yadav, P. Sarkale, R. Lakra, S. Baradkar,
250 G.R. Deshpande, D. Mali, B.N. Tilekar, T. Majumdar, H. Kaushal, Y. Gurav, N.
251 Gupta, S. Mohandas, K. Deshpande, O. Kaduskar, M. Salve, S. Patil, S. Gaikwad,
252 A.P. Sugunan, M. Ashok, S. Giri, J. Shastri, P. Abraham, R.R. Gangakhedkar, C.S.
253 Team, Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-
254 2 IgG, Indian Journal of Medical Research. 151 (2020)
255 444. https://doi.org/10.4103/ijmr.IJMR_2232_20 .
- 256 [8] LIAISON® SARS-CoV-2 S1/S2
257 IgG [https://www.diasorin.com/sites/default/files/allegati_prodotti/liaison_sars-cov-](https://www.diasorin.com/sites/default/files/allegati_prodotti/liaison_sars-cov-2_s1_s2_igg_0.pdf)
258 [2_s1_s2_igg_0.pdf](https://www.diasorin.com/sites/default/files/allegati_prodotti/liaison_sars-cov-2_s1_s2_igg_0.pdf) (accessed August 7, 2020).
- 259 [9] T. Byrt, J. Bishop, J.B. Carlin, Bias, prevalence and kappa, Journal of Clinical
260 Epidemiology. 46 (1993) 423–429. [https://doi.org/10.1016/0895-4356\(93\)90018-V](https://doi.org/10.1016/0895-4356(93)90018-V) .
- 261 [10] Cohenkap package for STATA software for agreement
262 analysis. <http://www.graunt.cat/stata/cohenkap.ado> (accessed August 7, 2020).
- 263 [11] M. Chatzidimitriou, F. Chatzopoulou, E. Gavriilaki, P. Chatzivasileiou, D. Rousis, G.
264 Meletis, D. Chatzidimitriou, Repeated negative serological testing in otherwise
265 healthy patients with COVID-19, The Journal of Infectious Diseases.
266 (2020). <https://doi.org/10.1093/infdis/jiaa453> .

- 267 [12] M.L. Bastos, G. Tavaziva, S.K. Abidi, J.R. Campbell, L.-P. Haraoui, J.C. Johnston,
268 Z. Lan, S. Law, E. MacLean, A. Trajman, D. Menzies, A. Benedetti, F.A. Khan,
269 Diagnostic accuracy of serological tests for covid-19: systematic review and meta-
270 analysis, *BMJ*. 370 (2020). <https://doi.org/10.1136/bmj.m2516> .
- 271 [13] M.K. Das, A. Chaudhary, A. Bryan, M.H. Wener, S.L. Fink, C. Morishima, Rapid
272 Screening Evaluation of SARS-CoV-2 IgG Assays Using Z-Scores to Standardize
273 Results, (n.d.). <https://doi.org/10.3201/eid2610.202632> .
- 274 [14] C.L. Charlton, J.N. Kanji, K. Johal, A. Bailey, S.S. Plitt, C. MacDonald, A. Kunst, E.
275 Buss, L.E. Burnes, K. Fonseca, B.M. Berenger, K. Schnabl, J. Hu, W. Stokes, N.
276 Zelyas, G. Tipples, Evaluation of six commercial mid to high volume antibody and
277 six point of care lateral flow assays for detection of SARS-CoV-2 antibodies,
278 *Journal of Clinical Microbiology*. (2020). <https://doi.org/10.1128/JCM.01361-20> .
- 279 [15] K.G. Beavis, S.M. Matushek, A.P.F. Abeleda, C. Bethel, C. Hunt, S. Gillen, A.
280 Moran, V. Tesic, Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay
281 for detection of IgA and IgG antibodies, *J. Clin. Virol.* 129 (2020)
282 104468. <https://doi.org/10.1016/j.jcv.2020.104468> .
- 283 [16] C. Bundschuh, M. Egger, K. Wiesinger, C. Gabriel, M. Clodi, T. Mueller, B.
284 Dieplinger, Evaluation of the EDI enzyme linked immunosorbent assays for the
285 detection of SARS-CoV-2 IgM and IgG antibodies in human plasma, *Clinica*
286 *Chimica Acta*. 509 (2020) 79–82. <https://doi.org/10.1016/j.cca.2020.05.047> .
- 287 [17] M. Egger, C. Bundschuh, K. Wiesinger, C. Gabriel, M. Clodi, T. Mueller, B.
288 Dieplinger, Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the
289 EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2

- 290 antibodies in human plasma, Clin. Chim. Acta. 509 (2020) 18–
291 21. <https://doi.org/10.1016/j.cca.2020.05.049> .
- 292 [18] V. Haselmann, M. Kittel, C. Gerhards, M. Thiaucourt, R. Eichner, V. Costina, M.
293 Neumaier, Comparison of test performance of commercial anti-SARS-CoV-2
294 immunoassays in serum and plasma samples, Clin. Chim. Acta. 510 (2020) 73–
295 78. <https://doi.org/10.1016/j.cca.2020.07.007> .
- 296 [19] S. Hörber, J. Soldo, L. Relker, S. Jürgens, J. Guther, S. Peter, R. Lehmann, A.
297 Peter, Evaluation of three fully-automated SARS-CoV-2 antibody assays, (n.d.) 8.
- 298 [20] A.J. Jääskeläinen, S. Kuivanen, E. Kekäläinen, M.J. Ahava, R. Loginov, H. Kallio-
299 Kokko, O. Vapalahti, H. Jarva, S. Kurkela, M. Lappalainen, Performance of six
300 SARS-CoV-2 immunoassays in comparison with microneutralisation, J. Clin. Virol.
301 129 (2020) 104512. <https://doi.org/10.1016/j.jcv.2020.104512> .
- 302 [21] A.J. Jääskeläinen, E. Kekäläinen, H. Kallio-Kokko, L. Mannonen, E. Kortela, O.
303 Vapalahti, S. Kurkela, M. Lappalainen, Evaluation of commercial and automated
304 SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient
305 samples, Eurosurveillance. 25 (2020). [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2020.25.18.2000603)
306 [7917.ES.2020.25.18.2000603](https://doi.org/10.2807/1560-7917.ES.2020.25.18.2000603) .
- 307 [22] J.-H. Ko, E.-J. Joo, S.-J. Park, J.Y. Baek, W.D. Kim, J. Jee, C.J. Kim, C. Jeong, Y.-
308 J. Kim, H.J. Shon, E.-S. Kang, Y.K. Choi, K.R. Peck, Neutralizing Antibody
309 Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with
310 Pneumonic COVID-19 Patients, J Clin Med. 9
311 (2020). <https://doi.org/10.3390/jcm9072268> .

- 312 [23] A. Krüttgen, C.G. Cornelissen, M. Dreher, M. Hornef, M. Imöhl, M. Kleines,
313 Comparison of four new commercial serologic assays for determination of SARS-
314 CoV-2 IgG, J. Clin. Virol. 128 (2020)
315 104394. <https://doi.org/10.1016/j.jcv.2020.104394> .
- 316 [24] A.E. Merrill, J.B. Jackson, A. Ehlers, D. Voss, M.D. Krasowski, Head-to-Head
317 Comparison of Two SARS-CoV-2 Serology Assays, The Journal of Applied
318 Laboratory Medicine. (2020). <https://doi.org/10.1093/jalm/jfaa125> .
- 319 [25] B. Meyer, G. Torriani, S. Yerly, L. Mazza, A. Calame, I. Arm-Vernez, G. Zimmer, T.
320 Agoritsas, J. Stirnemann, H. Spechbach, I. Guessous, S. Stringhini, J. Pugin, P.
321 Roux-Lombard, L. Fontao, C.-A. Siegrist, I. Eckerle, N. Vuilleumier, L. Kaiser,
322 Validation of a commercially available SARS-CoV-2 serological immunoassay,
323 Clinical Microbiology and Infection.
324 (2020). <https://doi.org/10.1016/j.cmi.2020.06.024> .
- 325 [26] M.S. Tang, K.G. Hock, N.M. Logsdon, J.E. Hayes, A.M. Gronowski, N.W.
326 Anderson, C.W. Farnsworth, Clinical Performance of Two SARS-CoV-2 Serologic
327 Assays, Clinical Chemistry. 66 (2020) 1055–
328 1062. <https://doi.org/10.1093/clinchem/hvaa120> .
- 329 [27] E.S. Theel, J. Haring, H. Hilgart, D. Granger, Performance Characteristics of Four
330 High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-
331 CoV-2, Journal of Clinical Microbiology. 58
332 (2020). <https://doi.org/10.1128/JCM.01243-20> .
- 333 [28] L. Weidner, S. Gänsdorfer, S. Unterweger, L. Weseslindtner, C. Drexler, M. Farcet,
334 V. Witt, E. Schistal, P. Schlenke, T.R. Kreil, C. Jungbauer, Quantification of SARS-

- 335 CoV-2 antibodies with eight commercially available immunoassays, J. Clin. Virol.
336 129 (2020) 104540. <https://doi.org/10.1016/j.jcv.2020.104540> .
- 337 [29] M. Lisboa Bastos, G. Tavaziva, S.K. Abidi, J.R. Campbell, L.-P. Haraoui, J.C.
338 Johnston, Z. Lan, S. Law, E. MacLean, A. Trajman, D. Menzies, A. Benedetti, F.
339 Ahmad Khan, Diagnostic accuracy of serological tests for covid-19: systematic
340 review and meta-analysis, BMJ. (2020) m2516. <https://doi.org/10.1136/bmj.m2516>
- 341 [30] M.G. Nasab, A. Saghazadeh, N. Rezaei, SARS-CoV-2-A Tough Opponent for the
342 Immune System, Arch. Med. Res.
343 (2020). <https://doi.org/10.1016/j.arcmed.2020.05.020> .
- 344
- 345

346 Writing committee:

347 Susmita Chaudhuri*, Ramachandran Thiruvengadam*, Pallavi Kshetrapal, Gaurav
348 Batra, Tripti Shrivastava, Babu Koundinya Desiraju, Gagandeep Kang[§], Shinjini
349 Bhatnagar#

350 *Equally contributed to the manuscript

351 [§]Co-corresponding author

352 # Corresponding authors

353

354 Members of DBT India consortium for COVID-19 Research

355 Coordinating Institute: Translational Health Science and Technology Institute (THSTI)

356 Coordinating Principal Investigator: Dr Shinjini Bhatnagar

357 Co- Principal Investigator: Dr Gagandeep Kang

358 Co-Investigators (Clinical): Drs Nitya Wadhwa, Uma Chandramouli Natchu,
359 Ramachandran Thiruvengadam, Shailaja Sopory, Pallavi Kshetrapal, Babu Koundinya
360 Desiraju, Vandita Bhartiya, Mudita Gosain

361 Co-Investigators (Laboratory): Drs Gaurav Batra, Guruprasad Medigeshe, Susmita
362 Chaudhuri, Niraj Kumar, Tarun Sharma, Chandresh Sharma, Shailendra Mani, Tripti
363 Shrivastava

364 Clinical Operations Lead: Dr. Monika Bahl

365 International Centre for Genetic Engineering and Biotechnology (ICGEB): Dr Anmol
366 Chandele

367 Delhi University, South Campus, New Delhi: Dr Vijay Kumar Chaudhary

368 National Institute of immunology (NII): Drs. Amulya Panda, Nimesh Gupta

369 Maulana Azad Medical College and Lok Nayak Jai Prakash Narayan Hospital, New
370 Delhi: Drs. Nandini Sharma, Pragya Sharma, Sonal Saxena, J.C. Passey, Suresh
371 Kumar

372 ESI Medical College and Hospital, Faridabad, Haryana: Dr Asim Das, Anil K Pandey,
373 Nikhil Verma

374 Civil Hospital Gurugram (GCH), Haryana: Drs Deepa Sindhu, Jai Singh Malik

375 Civil Hospital Palwal (PCH), Haryana: Dr Brahmdeep Sindhu

376 Al-Falah School of Medical Science & Research Centre and Hospital, Dhouj, Haryana:
377 Drs S.K.S. Puri, Bhupinder Kaur Anand, Shubham Girdhar

378 Medanta Hospital, Gurugram, Haryana: Drs Sushila Kataria, Pooja Sharma

379 Shaheed Hasan Khan Mewati Government Medical College, Nalhar, Nuh, Haryana: Dr
380 Yamini

381 Lady Hardinge Medical College, New Delhi: Drs. Harish K. Pemde, Tanmaya Talukdar

382 SGT Medical college, Gurugram, Haryana: Drs. Pankaj Abrol, Mukesh Sharma

383 Dr. Dang's Lab, New Delhi: Drs Navin Dang, Manavi Dang, Arjun Dang, Leena
384 Chatterjee, Devjani De

385 **Author contribution:**

386 SB, GK, SC and RT conceptualized the study; All members of DBT India consortium for
387 COVID-19 Research devised methods, collected samples and clinical data; SC, GB,
388 TS, PK, ND, MD, AD, LC and DD provided reagents and analysed samples; RT, SC
389 and BKD curated and analysed data; SC, RT and GK drafted the manuscript; GK and
390 SB coordinated and supervised the study. All authors contributed in revision and
391 approved the final draft of the manuscript.

392 **Acknowledgement:**

393 We deeply thank the Department of Biotechnology, Government of India for supporting
394 the consortium. We are grateful to the leadership and administration of all partner
395 institutions in the consortium for their help and support. We thank all the clinical,
396 laboratory and data management staff for their contributions to this work and the
397 consortium at large.

398 Declarations of interest: none

399 **Supplementary material**400 **sTable 1: Head-head comparison of Zydus-Kavach & DiaSorin CLIA:**

	Zydus-Kavach Positive	Zydus-Kavach Negative	
DiaSorin CLIA Positive	278	34	312
DiaSorin CLIA Negative	9	58	67
	287	92	379

401 **Agreement/concordance analysis**

402 Global agreement: 88.7% (95%CI: 85.1, 91.5)

403 Specific agreement for positivity: 92.8% (95%CI: 90.5, 94.6)

404 Specific agreement for negativity: 73.0% (95%CI: 65.6, 79.3)

405 Cohen's Kappa statistic: 0.66 (95%CI: 0.57, 0.75)

406 **Observed disagreement:**

407 DiaSorin+Kavach-: 8.97% Kavach+DiaSorin-: 2.37%

408 Bias index (Difference in the proportion of positivity)= 0.07

409 DiaSorin is able to identify more cases than Zydus Kavach

410 Prevalence index: 0.58

411 **Prevalence and Bias-adjusted Kappa (PABAK): 0.77** (Inference: *Substantial*
412 agreement)

413

414

415 **sTable 2: Head-head comparison of Zydus-Kavach & RBD ELISA:**

	Zydus-Kavach Positive	Zydus-Kavach Negative	
RBD ELISA positive	280	41	321
RBD ELISA Negative	7	51	58
	287	92	379

416 **Agreement/concordance analysis**

417 Global agreement: 87.3% (95%CI: 83.6, 90.3)

418 Specific agreement for positivity: 92.1% (95%CI: 89.7, 94.0)

419 Specific agreement for negativity: 68.0% (95%CI: 60.2, 74.9)

420 Cohen's Kappa statistic: 0.61 (95%CI: 0.51, 0.70)

421 **Observed disagreement:**

422 RBD ELISA+Kavach-: 10.8% Kavach+RBD ELISA: 1.9%

423 Bias index (Difference in the proportion of positivity)= 0.09

424 RBD ELISA is able to identify more cases than Zydus Kavach

425 Prevalence index: 0.60

426 **Prevalence and Bias-adjusted Kappa (PABAK): 0.75** (Inference: *Substantial*
427 agreement)

428

429

430 **sTable 3: Head-head comparison of DiaSorin & RBD ELISA:**

	DiaSorin Positive	DiaSorin Negative	
RBD ELISA positive	307	14	321
RBD ELISA negative	6	52	58
	313	66	379

431 **Agreement/concordance analysis**

432 Global agreement: 94.7% (95%CI: 92.0, 96.6)

433 Specific agreement for positivity: 96.8% (95%CI: 95.2, 97.9)

434 Specific agreement for negativity: 83.9% (95%CI: 76.4, 89.3)

435 Cohen's Kappa statistic: 0.81 (95%CI: 0.73, 0.89)

436 **Observed disagreement:**

437 RBD ELISA+DiaSorin- : 3.7% DiaSorin+RBD ELISA: 1.6%

438 Bias index (Difference in the proportion of positivity)= 0.02

439 Minimal bias between the RBD ELISA and DiaSorin

440 Prevalence index: 0.67

441 **Prevalence and Bias-adjusted Kappa (PABAK): 0.89** (Inference: *Almost perfect*
442 agreement)

443

444

445 **sTable 4: Sensitivity of Zydus Kavach, DiaSorin, RBD ELISA across various**
 446 **periods of illness**


Duration of illness (days)	N	Zydus Kavach		DiaSorin CLIA		RBD ELISA	
		n	Sensitivity (%)	n	Sensitivity (%)	n	Sensitivity (%)
20-30	193	145	75.1	163	84.5	167	86.5
31-40	6	6	100	6	100	5	83.3
41-50	116	83	71.6	89	76.7	92	79.3
51-60	56	48	85.7	50	89.3	51	91.1
61-72	4	2	50	2	50	3	75.0

447

448

449

450 **sFigure 1: Number of samples over a range of duration of illness**



451